信达生物制药（苏州）有限公司 Innovent BiologicsInc
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Innovent Announces Phase 1b Study Results of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Published in Nature Communications 2022-06-29 08:00
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma 2022-06-27 08:00
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-Line Treatment for Esophageal Squamous Cell Carcinoma 2022-06-21 08:00
Innovent and Etana Jointly Announce the Approval of Bevagen® (Bevacizumab Biosimilar) by the Indonesian Food and Drugs Authority (BPOM) 2022-06-14 08:00
Innovent Announces the NMPA Acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody) 2022-06-14 08:00
Innovent and IASO Bio Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022 2022-06-13 08:00
Innovent Releases Results of High-dose Cohorts in Phase 1 Clinical Study of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity at ENDO 2022 2022-06-13 08:00
Innovent Announces Phase 2 study of Mazdutide（IBI362） in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints 2022-06-08 08:00
Innovent and AnHeart Jointly Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1-TKI) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting 2022-06-07 08:00
Innovent Presents Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting 2022-06-06 08:08
Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma 2022-06-06 08:00
Innovent Presents Clinical Data of Phase I Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting 2022-06-06 08:00
Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director 2022-06-01 08:00
Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting 2022-05-16 08:00
Innovent Receives NMPA Breakthrough Designation for IBI310, the Anti-CTLA-4 Monoclonal Antibody, Combined with Sintilimab in Advanced Cervical Cancer Treatment 2022-04-14 08:30
Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022 2022-04-11 08:14
Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That Have Progressed After at Least One Prior Line of Systemic Therapy 2022-04-06 12:43
Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022 2022-04-04 08:00
Innovent Announced 2021 Annual Results 2022-03-30 08:00
Innovent Announces First Patient Dosing of Claudin18.2/CD3 Bispecific Antibody IBI389 in Phase 1a/1b Clinical Trial for Advanced Solid Tumor 2022-03-29 08:10
1 6 7 8 9 10 17